1
|
Kihara E, Galic I, Nyamunga D, Mehdi F, Velandia Palacio LA, Cameriere R. Validation of the Italian, European, North German, Malaysian, and South African black formulas on Cameriere method using panoramic radiographs in Kenyan children. Int J Legal Med 2022; 136:1495-1506. [PMID: 35710955 DOI: 10.1007/s00414-022-02854-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Accepted: 06/07/2022] [Indexed: 11/28/2022]
Abstract
This study aimed to validate the accuracy of five different formulas based on the Cameriere method for age estimation in Kenyan children. We analyzed panoramic radiographs of 350 Kenyan children (184 males and 166 females) aged between 6 and 13 years. The dental development of each child was estimated by the analysis of the first seven left permanent teeth in the left mandible. Dental age was calculated by the Italian, European, North German, Malaysian, and South African black formulas previously published in peer-review journals. The children's mean chronological age (CA) was 9.34 ± 2.02 years and 9.26 ± 2.01 years for males and females. In males, the South-African formula overestimated CA least, by 0.12 years, followed by the Italian formula by 0.22 years, the European formula by 0.37 years, the Malaysian formula by 0.48 years, and the North-German formula overestimated the most, by 0.57 years. In females, the South-African formula underestimated CA by - 0.12 years. The Italian overestimated by 0.12 years, followed by the North-German formula by 0.29 years, the European formula by 0.31 years, and the Malaysian formula by 0.40 years. The Italian formula provided the best accuracy in the absolute difference within ± 1 year, by 75.72% and 75%, following the North-German formula by 66.47% and 70.27% for males and females, respectively. Therefore, the findings suggest that the Italian formula best estimates dental age in Kenyan children.
Collapse
Affiliation(s)
- Eunice Kihara
- Department of Oral and Maxillofacial Surgery, School of Dental Sciences, University of Nairobi, Nairobi, Kenya
| | - Ivan Galic
- Department of Oral Surgery, University of Split School of Medicine, Šoltanska 2, Split, 21000, Croatia. .,University Hospital of Split, Spinčićeva 1, Split, 21000, Croatia.
| | - Donna Nyamunga
- Division of Forensic and Pathology Services, Ministry of Health, Nairobi, Kenya
| | - Fuad Mehdi
- Department of Oral Surgery, University of Split School of Medicine, Šoltanska 2, Split, 21000, Croatia.,University Hospital of Split, Spinčićeva 1, Split, 21000, Croatia
| | | | - Roberto Cameriere
- AgEstimation Project, Department of Medicine and Health Sciences "Vincenco Tiberio", University of Molise, Campobasso, 86100, Italy.,Department of Forensic Medicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation
| |
Collapse
|
3
|
Różyło-Kalinowska I, Kalinowski P, Krasicka E, Galić I, Mehdi F, Cameriere R. The Cameriere method using cone-beam computed tomography (CBCT) scans for dental age estimation in children. AUST J FORENSIC SCI 2020. [DOI: 10.1080/00450618.2020.1789221] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Ingrid Różyło-Kalinowska
- Independent Unit of Epidemiology, Medical University of Lublin, Lublin, Poland
- Independent Unit of Propaedeutics of Dentomaxillofacial Radiology, Medical University of Lublin, Lublin, Poland
| | - Paweł Kalinowski
- Independent Unit of Epidemiology, Medical University of Lublin, Lublin, Poland
| | | | - Ivan Galić
- Department of Oral Surgery, University of Split School of Medicine and University Hospital Centre, Split, Croatia
- AgEstimation Project, University of Macerata, Macerata, Italy
| | - Fuad Mehdi
- Department of Oral Surgery, University of Split School of Medicine and University Hospital Centre, Split, Croatia
| | | |
Collapse
|
4
|
Sejil I, Oumaya A, Bouguerra C, Mehdi F, Bellaaj R, Gallali S. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics]. Encephale 2012; 39 Suppl 1:S36-41. [PMID: 23219594 DOI: 10.1016/j.encep.2012.08.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Accepted: 08/08/2012] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The term tardive dyskinesia (TD) is used to describe abnormal movement, primarily associated with typical antipsychotic drugs, which are used to treat psychotic states such as schizophrenia. TD is characterised by repetitive involuntary purposeless muscle contractions that force parts of the body into abnormal, and sometimes painful, movements or postures. These movements are involuntary and are difficult or impossible to control. TD usually begins with the face, mouth, lips and tongue, and includes grimacing, lip-smacking, tongue movements and rapid blinking. It may also involve the rest of the body and produce involuntary gestures, tics and writhing movements. TD is severe physically and socially disabling. Schizophrenia is thought to be the psychiatric diagnosis the most frequently associated with TD. MATERIALS AND METHODS The purpose of this article is to study the characteristics of TD in a Tunisian sample of 157 schizophrenics. A variety of demographic and clinical information was obtained by a questionnaire. Diagnoses of schizophrenia and TD were determined by using DSM-VI-R criteria. TD was assessed using the Abnormal Involuntary Movements Scale (AIMS). RESULTS The average age in this sample was 37 ± 6 years. The intermediate duration of evolution of the disease was 8 ± 3 years with a medium full number of hospitalizations of 4 ± 3. We found 58% of the paranoid sub-type. The intermediate duration of exposure to classical neuroleptics was 7 ± 3 years. The average of daily neuroleptic amount was 572.9 ± 145.3 equivalent milligrams of chlorpromazine. Extended release antipsychotics were used in 64.3% of cases, with fluphenazine deaconate in 90% and haloperidol deaconate in 10%. Anticholinergics were used by 74.5% of patients, with use of biperidene in 96% of cases. Therapeutic observance was good in 89.2% of patients. The prevalence of TD was an estimated 35%. The average of AIMS score was 17 ± 9, with a minimal score of 3 and a maximal one of 34. The distribution of patients according to severity found a prevalence of 52.7% of subjects with moderate TD, 38.2% with light TD and 9.1% with severe TD. The distribution of patients according to type, according to DSM-IV criteria, found 78.4% of cases with choreiform TD, 17.5% of cases with athetosic TD and 4.1% of cases with rhythmic TD. The intermediate duration of evolution of TD was estimated at 18 ± 6 months with a minimal duration of 3 months and a maximum of 72 months. The distribution of subjects according to duration of evolution of TD found that approximately three quarter of patients presented with TD that had evolved since one duration, lower or equal to one year. The average age of patients at the moment of installation of TD was estimated at 36 ± 6 years with 22 years as a minimal and 46 years as a maximal age. Among them, 81.8% of patients were aged over 30 at the time of the installation of TD. CONCLUSION The majority of patients with schizophrenia in Tunisia are still treated with typical antipsychotic drugs, and that's why the prevalence of TD remains relatively high.
Collapse
Affiliation(s)
- I Sejil
- Service de psychiatrie générale, faculté de médecine de Tunis, université Tunis El Manar, hôpital militaire principal d'instruction de Tunis, Le Mont Fleury, 1008 Tunis, Tunisie.
| | | | | | | | | | | |
Collapse
|
6
|
Beeram M, Saif WM, Sarantopoulos J, Schwartz G, Patnaik A, Tolcher AW, Mehdi F, Feit K, Takimoto CH. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of an oral antimicrotubular agent, DJ-927 (D), and capecitabine (C) in patients (Pts) with advanced cancers. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2016 Background: DJ-927, an oral microtubule stabilizer, has impressive cytotoxic activity in taxane-resistant tumors and an acceptable toxicity profile. C and Taxane combinations are active in solid tumors such as breast cancer. Non-overlapping mechanism of action and toxicity profiles and the convenience of an orally administered therapy have prompted a phase I evaluation of the combination. D was given orally once on day 1 and C for 14-days (D1–14), every three weeks. Methods: Eligible pts had evaluable cancer, minimal prior therapy and PS 0 - 2 ECOG. D was started at 18 mg/m2 on day 1 along with 1,250 mg/m2 of C orally B.I.D for 14 days, of a 21-day cycle. Incremental doses of both drugs were explored until the maximum tolerated dose (MTD) was reached. PK samples were collected during cycles 1 and 2, for assays of C and for D when given concurrently with C during cycle 1 and D given alone during cycle 2. Results: Twenty-seven pts [18 Male/ 9 Female; median age (range)- 58 yrs (33–70); PS 0 (n=8) ; PS 1 (n=19)] received 81 cycles [median (range)- 3 (1–8)] in 5 cohorts, with D and C 18/ 1250 mg/m2 (n = 3), 27/ 1250 mg/m2 (n = 7), 27/ 1900 mg/m2 (n = 7), 35/ 1900 mg/m2 (n = 3),and 27/ 2500 mg/m2 (n = 7). Dose-limiting toxicity (DLT) was grade 4 neutropenia in 2 of 3 pts at 35/ 1900 mg/m2 dose. Other common drug-related toxicities were leukopenia, nausea & vomiting (12 pts each, 44.4%), neutropenia, diarrhea and hand-foot syndrome (11 pts each, 40.7%), and fatigue (7 pts, 25.9%). A pt with hepatocellular carcinoma had an unconfirmed partial response at cycle 2 and 10 pts experienced disease stabilization lasting ≥ 12 weeks. The median elimination half-life (t½) of D was 182 hrs for cycle 1 (with C) and 204 hrs for cycle 2 (without C). Median tmax values for D with and without C occurred at 2 hours. Median clearance values (CL/F) for D in plasma were similar with and without C at 18.4 L/h/m2 and 19.8 L/h/m2, respectively. Conclusions: The combination of D and C is feasible and safe at the MTD of 27 mg/m2 and 2500 mg/m2, respectively. Co-administering C with D did not alter the PK of either drug. Preliminary evidence of antitumor activity suggests that further studies of this combination are warranted. [Table: see text]
Collapse
Affiliation(s)
- M. Beeram
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| | - W. M. Saif
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| | - J. Sarantopoulos
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| | - G. Schwartz
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| | - A. Patnaik
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| | - A. W. Tolcher
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| | - F. Mehdi
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| | - K. Feit
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| | - C. H. Takimoto
- University of Texas Health Science Center, San Antonio, TX; Yale Cancer Center, New Haven, CT; Institute for Drug Development, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; Daiichi Medical Research, Park Ridge, NJ
| |
Collapse
|